 W. L. Gore
(Flagstaff, Ariz) is currently conducting clinical trials of
their c (conformable)-TAG device, with which preliminary experience outside the United States appears to
show improved arch conformability and greater tolerance to device oversizing.
Issue 5: LSA management during zone 2 coverage.
There was near unanimity of opinion for selective revascu-

larization (either before or after TEVAR) depending on the
status of the vertebral anatomy